Antisense in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... the versatility and broad applicability of antisense drugs to inhibit targets that could offer new ... and the momentum to realize the full potential of antisense as a drug discovery technology," concluded Ms. ... Isis' partnered pipeline continues to mature as antisense drugs that Isis' satellite companies are ...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

... Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs were highlighted with eight presentations ... that reducing levels of these targets with antisense drugs can significantly lower blood glucose ... Isis' anti-obesity drug discovery program showing antisense drugs reduced fat mass and body weight in animals ...

Isis and Collaborators Present New Research at the ATVB Annual Conference

... two late-stage research programs, one on a direct antisense inhibitor of apoC-III, which may provide a ... drug to lower triglycerides, and a second on an antisense inhibitor to Factor XI, which has the potential ... Isis and collaborators also presented data on antisense inhibitors against 11 beta-HSD1 and apoF, ...

Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

... "The progress our partners are making with antisense drugs discovered using Isis' antisense technology demonstrates the value of our ... has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug ...

ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis

... Calif., Sept. 22 /PRNewswire-FirstCall/ -- antisense Therapeutics Ltd. (ASX: ANP) and ... for the first time, that a second-generation antisense drug designed to specifically inhibit the ... Mark Diamond, Chief Executive Officer of antisense Therapeutics, said, "We are delighted to have our ...

Isis Initiates Clinical Trial of CRP Drug

... has initiated a Phase 1 study of ISIS 353512, an antisense drug that inhibits the production of C-reactive ... ISIS 353512 Targets CRP ISIS 353512 is an antisense drug that targets CRP. For many years, CRP has ... has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug ...

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

... a novel lipid-lowering drug that utilizes antisense technology. The companies also announced that ... 7,407,943. The patent broadly covers the use of antisense compounds targeting the apoB messenger RNA except ... both single-stranded and double-stranded (siRNA) antisense drugs complementary to any site of the mRNA of ...

Genzyme and Isis Complete Licensing of Mipomersen

... drug that demonstrates the power and precision of antisense drugs. We believe now, as we did in January, ... Mipomersen Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a ... has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug ...

Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference

... blood glucose lowering effect of SGLT2 antisense inhibitors in multiple preclinical models - ... presentation of new preclinical data showing that antisense drugs potently reduce levels of sodium dependent ... and Efficacy of ISIS 388626, an Optimized SGLT2 antisense Inhibitor, in Multiple Diabetic and ...

Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements

... benefit of 15.5 months for patients receiving the antisense treatment over chemotherapy. In recurrent or ... chemotherapy with either Temozolomide or BCNU. antisense Pharma plans to conduct an interim analysis using ... Dr. Hubert Heinrichs, Chief Medical Officer of antisense Pharma. The Phase III study aims to ...

Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma

... The TGF-beta 2 inhibitor AP 12009, developed by antisense Pharma, reveals very good safety and tolerability ... Dr. Hubert Heinrichs, Chief Medical Officer of antisense Pharma. To further study the potential of the antisense treatment in pancreatic carcinoma, a Phase II ...

Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis

... the first study, the impact of treatment with an antisense drug was evaluated in the context of two ... of 50 mg/kg twice weekly, the murine apoB-100 antisense drug reduced total cholesterol ... and showed that the effects of the apoB-100 antisense drug were linearly dose-dependent with regard to ...

Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months

... $2 billion. Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a ... has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug ... metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety ...

Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012

... to the effects of either small molecule or antisense inhibitors of microsomal triglyceride transfer ... CHOLESTEROL ISIS 301012 is a second-generation antisense drug that reduces the production of apoB-100, a ... has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug ...

Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568

... ISIS 325568 is an antisense Drug Targeting Glucagon Receptor for Treatment ... includes the licensing of two second-generation antisense drugs, ISIS 325568 and ISIS 377131, both of which ... Reducing the expression of liver GCGR using antisense inhibitors, and thereby reducing excessive liver ...

Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes

... has initiated a Phase 1 study of ISIS 325568, an antisense drug designed to improve blood glucose control in ... Reducing the expression of liver GCGR using antisense inhibitors, and thereby reducing excessive liver ... has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug ...

Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights

... who are currently receiving conventional taxanes. C-myb Antisense An antisense drug directed against c-myb, a master regulatory proto- oncogene, is the ... stage clinical program. In 2007, a new dose-ranging Phase 1 trial of c-myb antisense was initiated at the University of Pennsylvania. The trial is currently ...

Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary

... and Cholesterol Mipomersen, formerly ISIS 301012, is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to ... partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are ...

Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients

... About ISIS 301012 and Cholesterol ISIS 301012 is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the ... partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are ...

Another LNA-based RNA Inhibitor Enters Clinical Trials

... a novel locked nucleic acid oligonucleotide against survivin, inhibits survivin expression and confers taxol sensitivity" "EZN-3920, an LNA antisense oligonucleotide RNA antagonist, down modulates HER3 expression and PI3K/Akt signaling pathway and enhances antiproliferative effect of Gefitinib in ...

Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer

... line is transplanted into livers of mice, in order to evaluate the efficacy of systemic microRNA-based treatment in these mice. Chemically modified antisense oligos (ASOs) were delivered systemically, targeting the over-expressed microRNA. Using this animal model, the scientists have shown that the ...

Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156

... funding from The Leukemia & Lymphoma Society, is entitled "A Phase 1-2, Multicenter, Open-Label Study of the X- Linked Inhibitor of Apoptosis (XIAP) antisense AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Follicular Lymphoma." It is being ...

Isis Pharmaceuticals Conference Call Notice

... release Please visit http://www.isispharm.com or http://www.antisense.com.au/_home.asp to view the release titled: Teva Pharmaceuticals & antisense Therapeutics Announce That ATL/TV 1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis Demonstrated Significant ...

Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells

... HIV infection and, we believe, may prove to be more effective than temporary 'knock down' approaches based on small molecule inhibitors, antibodies, antisense or RNAi." Sangamo's ZFNs are designed to permanently modify the DNA sequence encoding CCR5, a co-receptor that enables HIV to enter and infect ...

Genta Clinical Programs Featured at American Society of Hematology Meeting

... selected for a featured press briefing sponsored by ASH on Sunday December 9 at 9:30 am. -- Oblimersen (Genasense(R)), a phosphorothioate Bcl-2 antisense oligonucleotide (ASO), can be safely administered by bolus subcutaneous (SC) injection and brief IV Infusion. Publication. -- Phase 1 ...

Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies

... RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners ...

Lorus Therapeutics Announces Scientific Presentations for Lead Antisense and siRNA Drug Candidates at International Cancer Conference

... announced presentation of research on their lead antisense and siRNA compounds at the 98th Annual Meeting of ... Lorus' drug development strategies involving antisense and siRNA," commented Dr. Aiping Young, Lorus' ... medicines." About GTI-2040 GTI-2040 is an antisense drug that specifically targets the R2 component ...

AVI BioPharma Reports Positive Pre-Clinical Influenza Data

... data demonstrating effectiveness of NEUGENE(R) antisense compounds against seasonal influenza A virus in ... Diseases (USAMRIID), mice were pre-treated with antisense phosphorodiamidate morpholino oligomers (PMOs), ... research, reinforce our belief that NEUGENE antisense compounds are potentially well-suited to treating ...

Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor AP 12009 to be Presented

... June 1st - 5th. In the Phase I/II-trial the antisense drug AP 12009 is administered intravenously in ... Heinrichs, M.D., Ph.D., Chief Medical Officer at antisense Pharma. Patient recruitment is still ongoing in ... 3 of McCormick Place South Building. About antisense Pharma ...

2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion

... For further information please contact: antisense PHARMA GmbH Dr. Heike Specht / Public Relations ... professionals from all over the world. About antisense Pharma antisense Pharma is a biopharmaceutical company located in ...

Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma

... 2-inhibitor AP 12009, under development by antisense Pharma. Prof. Wong discussed the results of the ... M.D., Ph.D., Chief Executive Officer of antisense Pharma commented, “AP 12009 is an example of antisense Pharma´s commitment to meet unmet medical ...

Study Presented at ACC Shows Treatment With ISIS 301012 Added to Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C Levels of Less Than 70 mg/dL

... Dr. John J.P. Kastelein Title: ISIS 301012, an antisense Inhibitor of Apolipoprotein B, Produces Significant ... About ISIS 301012 and Cholesterol ISIS 301012 is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the ...

Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

... IV Melanoma Patients but is a Predictive Factor only for Bcl-2 antisense Treatment Efficacy: Re- analysis of GM301 and EORTC18951 ... +/- Oblimersen (Genasense; G3139), a Pro-Apoptotic Bcl-2 antisense Oligonucleotide, in Untreated Acute Myeloid Leukemia Patients ...

AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

... being held in Germany, was designed to study the effect of the Neugene(R) antisense drug Resten-MP(TM), when used in conjunction with the placement of one or ... specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, ...

Isis Pharmaceuticals Announces Its Participation at the Upcoming ACC 56th Annual Scientific Session in New Orleans and Its Live Analyst/Investor Webcast Presentation

... 820-6 Time: 4:45 - 5:00 p.m. Speaker: Dr. John J.P. Kastelein Title: ISIS 301012, an antisense Inhibitor of Apolipoprotein B, Produces Significant Additional Reduction of Low-Density Lipoprotein ...

Enzon to Present Preclinical Data From PEG-SN38 and PEGylation Technology Studies at AACR Meeting

... April 15, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 30, Poster Board 10.) -- Abstract #4731: Customized positive PEG linkers for the delivery of antisense molecules (Poster displayed on Tuesday, April 17, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 25, Poster Board 14.) -- Abstract #4726: In vitro ...

Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival

... of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17(9):2745-2751 -- Bedikian AY, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24(29):4738-4745. ...